Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC Member Directory
Directors' Biographies
JCCC Membership Resources
Researcher Profiles
Research Program Areas
Office of Regulatory Compliance
Shared Resources
Sue Stiles Program in Integrative Oncology
Athena Breast Health Network
Helpful Research Links
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Anthony Heaney, M.D., Ph.D.
Anthony Heaney, M.D., Ph.D.

Specialty:

Endocrinology
Diabetes
Metabolism

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Professor in Residence, Department of Medicine, Department of Neurosurgery
Director, Pituitary Tumor and Neuroendocrine Program
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Endocrinology Diabetes and Metabolism, Cedars-Sinai Medical Center, 2000 - 2001
Endocrinology Diabetes and Metabolism, Cedars-Sinai Medical Center, 1997 - 2000
Endocrinology Diabetes and Metabolism, Manchester Royal Infirmary, 1995 - 1997
Endocrinology Diabetes and Metabolism, Leeds General Infirmary, 1994 - 1995
Endocrinology Diabetes and Metabolism, Royal Victoria Hospital, 1992 - 1994
Residency:
Cardiovascular Disease, Royal Victoria Hospital, 1990 - 1992
Dermatology, Royal Victoria Hospital, 1990 - 1990
Endocrinology Diabetes and Metabolism, Royal Victoria Hospital, 1989 - 1990
Neurology, Royal Victoria Hospital, 1989 - 1989
Internal Medicine, Mater Infirmorum Hospital, 1988 - 1989
Internship:
Internal Medicine, Mater Infirmorum Hospital, 1987 - 1988
Medical Degree:
M.D., Queens University Belfast, 1987
Degree:
Ph.D., Queens University Belfast, 1995

Contact Information:

Phone:
(310) 267-4980
Email:
aheaney@mednet.ucla.edu

Scientific Interest(s):

Dr. Anthony Heaney's primary clinical and research interests involve the pathogenesis of pituitary tumors and exploiting novel molecular targets to develop innovative treatments for pituitary tumors and other neuroendocrine tumors.

Selected Cancer-Related Publications:

Yu R, Nissen NN, Dhall D, Heaney AP. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas. 2008 May;36(4):428-31.

Hui H, Fernando MA, Heaney AP. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer. 2008 Jan;44(1):160-6. Epub 2007 Nov 26.

Heaney AP. Targeting pituitary tumors. Horm Res. 2007;68 Suppl 5:132-6. Epub 2007 Dec 10.

Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006 Jun;7(6):518-20.

Heaney AP, O'Rourke D, Arthur K, Beatty OL, Russell CF, Sloan JM, Hamilton P, Atkinson AB. Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma. Clin Endocrinol (Oxf). 1996 Feb;44(2):233-8.

In the News: